Los Angeles Capital Management & Equity Research Inc. purchased a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT) in the 3rd quarter, according to its most recent filing with the SEC. The fund purchased 11,460 shares of the biopharmaceutical company’s stock, valued at approximately $229,000.

A number of other institutional investors and hedge funds have also modified their holdings of PTCT. TIAA CREF Investment Management LLC boosted its position in PTC Therapeutics by 3.0% during the 1st quarter. TIAA CREF Investment Management LLC now owns 96,318 shares of the biopharmaceutical company’s stock worth $948,000 after purchasing an additional 2,774 shares during the period. Vanguard Group Inc. boosted its position in PTC Therapeutics by 5.3% in the 1st quarter. Vanguard Group Inc. now owns 2,020,039 shares of the biopharmaceutical company’s stock valued at $19,877,000 after buying an additional 101,331 shares during the last quarter. Geode Capital Management LLC boosted its position in PTC Therapeutics by 4.2% in the 1st quarter. Geode Capital Management LLC now owns 270,264 shares of the biopharmaceutical company’s stock valued at $2,659,000 after buying an additional 10,958 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in PTC Therapeutics by 67.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 522,626 shares of the biopharmaceutical company’s stock valued at $5,143,000 after buying an additional 210,166 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in PTC Therapeutics by 5.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 125,761 shares of the biopharmaceutical company’s stock valued at $1,238,000 after buying an additional 6,840 shares during the last quarter. Institutional investors own 86.18% of the company’s stock.

PTCT has been the subject of a number of analyst reports. Cowen reissued a “hold” rating on shares of PTC Therapeutics in a research report on Wednesday, October 25th. Citigroup reissued a “buy” rating and issued a $28.00 price objective on shares of PTC Therapeutics in a research report on Wednesday, September 27th. ValuEngine cut shares of PTC Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, September 7th. Barclays reissued a “hold” rating and issued a $22.00 price objective on shares of PTC Therapeutics in a research report on Friday, September 8th. Finally, Zacks Investment Research cut shares of PTC Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $18.75.

PTC Therapeutics, Inc. (PTCT) opened at $15.77 on Tuesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.08 and a quick ratio of 2.97. PTC Therapeutics, Inc. has a 12-month low of $8.12 and a 12-month high of $22.00.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/05/los-angeles-capital-management-equity-research-inc-purchases-shares-of-11460-ptc-therapeutics-inc-ptct.html.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation.

Institutional Ownership by Quarter for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Stock Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related stocks with our FREE daily email newsletter.